RT Journal
A1 Miller DC, Hollenbeck BK
T1 REcommendations on use of prostate-specific antigen for prostate cancer screening—reply
JF JAMA
JO JAMA
YR 2012
FD April 4
VO 307
IS 13
SP 1372
OP 1374
DO 10.1001/jama.2012.399
UL http://dx.doi.org/10.1001/jama.2012.399
AB 
Second, the European Randomized Study of Screening for Prostate Cancer (ERSPC) identified a significant reduction in mortality associated with PSA-based screening.2 We acknowledge that the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial failed to demonstrate similar benefits3; this does not mean, however, that findings from the ERSPC study should be discounted or ignored, particularly given the limitations associated with the PLCO trial. Third, the randomized treatment trial from the Scandinavian Prostate Cancer Study Group (ie, surgery vs watchful waiting) demonstrated clinically and statistically significant reductions in both prostate cancer–specific mortality and all-cause mortality among men treated surgically.4 It appears from these studies that the benefits of screening and treatment may be greatest for men aged 70 years or younger. We believe that these collective data support a continued role for PSA-based screening and definitive local therapy as 1 component of broader efforts to reduce mortality rates and the adverse effects of prostate cancer and its treatment. Because this perspective is shared by many urologists, medical oncologists, and radiation therapists, we maintain that input from these specialists would have provided useful context and expertise during the USPSTF's deliberations.